Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Michel Alissa M, Yi Haeseung, Amenta Jacquelyn, Collins Nicole, Vaynrub Anna, Umakanth Subiksha, Anderson Garnet, Arnold Katie, Law Cynthia, Pruthi Sandhya, Sandoval-Leon Ana, Shirley Rachel, Perdekamp Maria Grosse, Colonna Sarah, Krisher Stacy, King Tari, Yee Lisa D, Ballinger Tarah J, Braun-Inglis Christa, Mangino Debra A, Wisinski Kari, DeYoung Claudia A, Ross Masey, Floyd Justin, Kaster Andrea, VanderWalde Lindi, Saphner Thomas J, Zarwan Corrine, Lo Shelly, Graham Cathy, Conlin Alison, Yost Kathleen, Agnese Doreen, Jernigan Cheryl, Hershman Dawn L, Neuhouser Marian L, Arun Banu, Crew Katherine D, Kukafka Rita
Аннотация
METHODS: The parent trial, MiCHOICE, is a cluster randomized controlled trial evaluating the effectiveness and implementation of patient and provider decision support tools to improve informed choice about chemoprevention among women with AH or LCIS. For this pre-implementation analysis, 25 providers participated in semi-structured interviews prior to accessing decision support tools. Interviews sought to understand attitudes/beliefs and barriers/facilitators to chemoprevention.
RESULTS: Interviews with 25 providers (18 physicians and 7 advanced practice providers) were included. Providers were predominantly female (84%), white (72%), and non-Hispanic (88%). Nearly all providers (96%) had prescribed chemoprevention for eligible patients. Three themes emerged in qualitative analysis. The first theme describes providers' confidence in chemoprevention and the utility of decision support tools. The second theme elucidates barriers to chemoprevention, including time constraints, risk communication and perceptions of patients' fear of side effects and anxiety. The third theme is the need for early implementation of decision support tools.
CONCLUSIONS: This qualitative study suggests that providers were interested in the early inclusion of decision aids (DA) in their chemoprevention discussion workflow. The DAs may help overcome certain barriers which were elucidated in these interviews, including patient level concerns about side effects, clinic time constraints and difficulty communicating risk. A multi-faceted intervention with a DA as one active component may be needed.
TRIAL REGISTRATION: This trial was registered with the NIH clinical trial registry, clinicaltrials.gov, NCT04496739.